Skip to Content
Merck
CN

SML3721

PHA-680632

≥98% (HPLC)

Synonym(s):

N-(2,6-Diethylphenyl)-4,6-dihydro-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-(2,6-diethylphenyl)-N′-{3-[4-(4-methylpiperazino)benzamide)-4,6-dihydropyrrolo[3,4-c]pyrazol-5-yl}urea, PHA 680632, PHA680632

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C28H35N7O2
CAS Number:
398493-79-3
Molecular Weight:
501.62
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
MFCD16038900

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

SMILES string

N1(CCN(CC1)c2ccc(cc2)C(=O)Nc3n[nH]c4c3CN(C4)C(=O)Nc5c(cccc5CC)CC)C

InChI key

OBWNXGOQPLDDPS-UHFFFAOYSA-N

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

Quality Level

100

Related Categories

Biochem/physiol Actions

Potent and selective Aurora kinase inhibitor with anti-cancer efficacy in cultures and in animals in vivo.

PHA-680632 is a potent and selective Aurora kinase inhibitor (Aurora A/B/C IC50 = 27/135/120 nM; FGFR1 IC50 = 390 nM, 30- to 200-fold selectivity for Aurora A over 6 other kinases and IC50 >10 μM against 22 kinases) with antiproliferation activity in cancer cultures (IC50 ranges from 60 nM to 7.15 μM) and anti-tumor efficacy in mice and rats in vivo (15-60 mg/kg i.v. b.i.d. or 15-45 mg/kg i.p. t.i.d.)

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000319122
0000319124
0000319124
0000319122
0000296039

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity
Clinical Cancer Research, 12(13), 4080-4089 (2006)
Y Tao et al.
British journal of cancer, 97(12), 1664-1672 (2007-11-21)
Overexpression of Aurora-A kinase has been correlated with cancer susceptibility and poor prognosis in several human cancers. In this study, we evaluated the effect of inhibition of Aurora-A kinase on cell cycle progression and tumour cell survival after exposure to
Laura Mazzera et al.
Haematologica, 104(12), 2465-2481 (2019-04-06)
Considering that Aurora kinase inhibitors are currently under clinical investigation in hematologic cancers, the identification of molecular events that limit the response to such agents is essential for enhancing clinical outcomes. Here, we discover a NF-κB-inducing kinase (NIK)-c-Abl-STAT3 signaling-centered feedback

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service